BUND FINANCE › Stocks › NVS
Novartis AG (NVS)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +3.77% above its 50-day average.
- It is +1.67% above its 200-day average (long-term uptrend).
- It sits at 68% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$44.0B | US$43.5B | US$46.7B | US$51.7B | US$56.7B |
| Net income | US$24.0B | US$7.0B | US$14.9B | US$11.9B | US$14.0B |
| EPS (diluted) | 10.63 | 3.17 | 7.10 | 5.87 | 7.15 |
| Gross margin | 73.3% | 73.4% | 73.3% | 75.2% | 75.8% |
| Operating margin | 22.9% | 18.3% | 20.9% | 28.1% | 31.1% |
| Net margin | 54.6% | 16.0% | 31.8% | 23.1% | 24.7% |
| Free cash flow | US$12.5B | US$12.0B | US$11.7B | US$13.8B | US$17.6B |
| Total debt | US$31.0B | US$27.9B | US$26.3B | US$31.3B | US$35.4B |
| Cash | US$12.4B | US$7.5B | US$13.4B | US$11.5B | US$11.4B |
Compound annual growth: revenue 6.6% · net income -12.7% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 29.6x | 16.8x | 27.1x |
| EV / EBITDA | 15.3x | 11.2x | 16.5x |
| Operating margin | 25.5% | — | 3.6% |
| Net margin | 17.8% | — | -0.0% |
| Debt / equity | 2.14 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice